close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.4900 -0.0244 (-4.74%)
Official Closing Price Updated: 8:00 PM EDT, Oct 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 Next >
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers 
Via MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
From Can-Fite BioPharma Ltd.
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months... 
Via Benzinga
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
From Can-Fite BioPharma Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 40 stocks hit new 52-week lows. 
Via Benzinga
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
From Can-Fite BioPharma Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  During Friday, 48 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 22 companies hit new 52-week lows. 
Via Benzinga
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
From Can-Fite BioPharma Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 35 companies reached new 52-week lows. 
Via Benzinga
Can-Fite Announces ADS Ratio Change
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer
 
Via Benzinga
Can-Fite Updates: Namodenoson Increases Survival for the Most Severe Patients with Advanced Liver Cancer
From Can-Fite BioPharma Ltd.
Via Business Wire
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
By Ernest Dela Aglanu, Benzinga 
Via News Direct
Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. 
Via TheNewswire.com
Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results
Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. 
Via Benzinga
Can-Fite’s Partner Vetbiolix is Heading into a European Multicentric Clinical Trial with Piclidenoson for the Treatment of Pets’ Osteoarthritis
From Can-Fite BioPharma Ltd.
Via Business Wire
Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Meet This BioPharma Company With Several Exciting Drugs In Advanced Clinical Trials
Sign up for this week’s All Access giveaway here!  Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSE: CANF), was a guest on Benzinga’s All Access on Nov 4, 2022. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today